TARTRATE SALTS OF THIAZOLIDINEDIONE DERIVATIVES

摘要

1. A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, L (+) tartrate salt or a solvate thereof. 2. A compound according to claim 1, characterised in that it provides: (i) an infrared spectrum substantially in accordance with Figure 1; (ii) a Raman spectrum substantially in accordance with Figure 2; (iii) an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or Figure 3; or (iv) a Solid State <13>C NMR spectrum substantially in accordance with Figure 4. 3. A compound according to claim 1, characterised in that it provides two or more of: (i) an infrared spectrum substantially in accordance with Figure 1; and (ii) a Raman spectrum substantially in accordance with Figure 2; and (iii) an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or Figure 3; and (iv) a Solid State <13>C NMR spectrum substantially in accordance with Figure 4. 4. A compound according to any one of claims 1 to 3, in purified form. 5. A compound according to any one of claims 1 to 3, in a solid dosage form. 6. A compound according to any one of claims 1 to 3, in a pharmaceutically acceptable form capable of being milled. 7. A compound according to any one of claims 1 to 3, in a pharmaceutically acceptable form having good flow properties. 8. A process for preparing the L (+) Tartrate or a solvate thereof, characterised in that 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I) or a salt thereof is reacted with a source of L (+) tartrate ion and thereafter, if required, a solvate of the resulting L (+) tartrate is prepared, and the L (+) Tartrate or a solvate thereof is recovered. 9. A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyljthiazolidine-2,4-dione L (+) tartrate or a solvate thereof and a pharmaceutically acceptable carrier therefor. 10. A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione L (+) tartrate or a solvate thereof for use as an active therapeutic substance. 11. A use of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione L (+) tartrate or a solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.